2025-09-09 – Press Releases – www.prnewswire.com

SHENZHEN, China, Sept. 9, 2025 /PRNewswire/ — XtalPi Inc. (Stock Code: 2228.HK) has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaboration with PharmaEngine, Inc. (TWO:4162), has received regulatory clearances to initiate…

Read the full article here.

About Us

Your go-to source for comprehensive research and comparisons of top-quality health supplements. We provide unbiased insights through meticulous analysis, offering accurate, evidence-based information to help you make informed decisions.

References

Awards

© 2024 by Health Supplements Review.